Startup focused on B-cell therapies launched with $52M in Series A
Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.
Massachusetts-based Be Biopharma will use the proceeds to build a team as it seeks to develop B-cell therapies for a variety of diseases.
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
The Takeda Ventures Senior Partner will take part in the panel discussion Trends in Oncology Investing at the MedCity CONVERGE Conference July 11-12 in Philadelphia.
Life science incubators and accelerators are expanding and broadening their value-adds, as highlighted on Thursday by two significant announcements; one from Boston, one from Israel.
From money-back guarantees to a surprising source of funding, MedCity INVEST presenters and panelists discussed some of the major trends influencing the biopharma sector in 2017.
If there’s any truth to the notion that corporate VC-backed companies have a higher rate of overall success than those without corporate VC funding, here’s a company we should be keeping an eye on. Naurex Inc., a young pharmaceutical company focused on psychiatry and neurology, rounded up $38 million from lead investor Baxter Ventures and […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.